Embryo-feto-toxicity of anticancer drug, heptaplatin in laboratory mice.
The present study was conducted to test the possible teratogenic and toxic effects of anti-cancer drug heptaplatin (SKI 2053) on developing embryos and fetuses in gestating SWR/J mice. Dose levels of 5.0, 10.0 and 12.5 mg heptaplatin/kg b.wt. were intraperitoneally administered to pregnant mice on days 6-8, 9-11 and 12-14 of gestation. On day 17 of gestation, all fetuses were removed and examined for toxic phenomena (embryo-fetal toxicity) by taking observation on live fetuses and embryonic resorption. Fetuses were also examined for external, internal and skeletal malformations. None of the dams treated with heptaplatin at any of the dose levels used in the present study died during the experimental period. Higher doses of heptaplatin caused greater embryonic resorption and reduced number of live fetuses. However, no loss of body weight was noticed in fetuses at any of the dose levels administered. At highest dose of heptaplatin (12.5 mg kg(-1)), tail deformity was observed in the form of short and curve tails whereas no other anatomical or skeletal malformations were noticed in any of the fetuses. In addition to mild embryo-fetotoxicity, the study indicates mild teratogenic effects of hetaplatin as reflected in fetal abnormalities at low frequency. These results have significant implications for protracted use of this drug.
Department of Clinical Laboratory, Riyadh College of Health Sciences, King Saud University, Saudi Arabia.
K M
KM
Al-Anazi
F M
FM
Abou-Tarboush
M F
MF
Abdel-Samad
M A
MA
Farah
M Y
MY
Al-Faifi
B A
BA
Al-Ahmadi
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D005260:Female; D008314:Malonates / Q000633:toxicity*; D018811:Maternal Exposure; D051379:Mice; D009944:Organoplatinum Compounds / Q000633:toxicity*; D011247:Pregnancy; D013723:Teratogens / Q000633:toxicity*
D000970:Antineoplastic Agents; D008314:Malonates; D009944:Organoplatinum Compounds; D013723:Teratogens; C090717:SKI 2053R